# PENG Block Optimization: Volume and Dexamethasone Effects

> **NCT07023120** · PHASE4 · COMPLETED · sponsor: **Poznan University of Medical Sciences** · enrollment: 120 (actual)

## Conditions studied

- Hip Arthropathy
- Hip Osteoarthritis
- Hip Arthritis

## Interventions

- **DRUG:** Ropivacaine 0.2% Injectable Solution
- **DRUG:** Dexamethasone 4mg
- **DRUG:** Ropivacaine 0.2% Injectable Solution

## Key facts

- **NCT ID:** NCT07023120
- **Lead sponsor:** Poznan University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-25
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-02-20
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07023120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07023120, "PENG Block Optimization: Volume and Dexamethasone Effects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07023120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*